Group 1 - The core viewpoint of the articles highlights the strong performance of He Yu-B (02256), with a significant stock price increase and positive mid-year financial results [1][2] - He Yu reported a revenue of 612 million yuan, representing a year-on-year growth of 21.5%, and a net profit attributable to shareholders of 328 million yuan, reflecting a 58.8% increase [1] - The company has initiated a share buyback plan starting from March 2025, having repurchased 9.545 million shares, which is 1.4% of the total shares issued at the beginning of the year, involving a total expenditure of 75.3 million HKD [1] Group 2 - Citigroup believes that He Yu's current valuation is low, considering the high certainty of its two late-stage drug candidates, pimicotinib and irpagratinib, and the potential for differentiated innovation pipeline to achieve external licensing [2] - The bank anticipates a high success rate for the phase III clinical trial of irpagratinib for second-line hepatocellular carcinoma, suggesting that this should be factored into the company's valuation [2] - Key catalysts are expected for He Yu in 2025 and 2026, including the approval and commercialization performance of pimicotinib, the announcement of phase III data for irpagratinib, and updates on several other drug candidates [2]
港股异动 | 和誉-B(02256)涨超4%续创新高 上半年业绩快速增长 花旗称公司现估值偏低